NASDAQ:ADXSAdvaxis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Advaxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.71 +0.01 (+1.43 %) (As of 05/27/2020 04:00 PM ET) Add Compare Share Today's Range$0.67Now: $0.71▼$0.7250-Day Range$0.59MA: $0.68▼$0.7952-Week Range$0.21Now: $0.71▼$3.00Volume1.13 million shsAverage Volume1.15 million shsMarket Capitalization$42.78 millionP/E RatioN/ADividend YieldN/ABeta3.6 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Advaxis. Previous Next 2.4 Community Rank Outperform VotesAdvaxis has received 365 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdvaxis has received 407 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdvaxis has received 52.72% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote “Outperform” if you believe ADXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdvaxis does not currently pay a dividend.Dividend GrowthAdvaxis does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Advaxis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,588.00 in company stock.Percentage Held by InsidersOnly 0.26% of the stock of Advaxis is held by insiders.Percentage Held by InstitutionsOnly 11.43% of the stock of Advaxis is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Advaxis is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Advaxis is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdvaxis has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADXS Previous Symbol CUSIPN/A CIK1100397 Webwww.advaxis.com Phone609-452-9813Debt Debt-to-Equity Ratio0.14 Current Ratio9.26 Quick Ratio9.26Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.88 million Price / Sales2.05 Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book0.31Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-16,610,000.00 Net Margins-3,108.18% Return on Equity-82.13% Return on Assets-70.38%Miscellaneous Employees58 Outstanding Shares60,250,000Market Cap$42.78 million Next Earnings Date6/8/2020 (Estimated) OptionableOptionable NASDAQ:ADXS Rates by TradingView Receive ADXS News and Ratings via Email Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Advaxis (NASDAQ:ADXS) Frequently Asked Questions How has Advaxis' stock been impacted by COVID-19 (Coronavirus)? Advaxis' stock was trading at $0.6666 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADXS stock has increased by 6.5% and is now trading at $0.71. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Advaxis? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Advaxis. When is Advaxis' next earnings date? Advaxis is scheduled to release its next quarterly earnings announcement on Monday, June 8th 2020. View our earnings forecast for Advaxis. How were Advaxis' earnings last quarter? Advaxis, Inc. (NASDAQ:ADXS) announced its quarterly earnings results on Friday, March, 13th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. Advaxis had a negative return on equity of 82.13% and a negative net margin of 3,108.18%. View Advaxis' earnings history. Has Advaxis been receiving favorable news coverage? Media stories about ADXS stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutAdvaxis. Who are some of Advaxis' key competitors? Some companies that are related to Advaxis include AVEO Pharmaceuticals (AVEO), Evelo Biosciences (EVLO), Tiziana Life Sciences (TLSA), Mustang Bio (MBIO), Theratechnologies (THTX), Evolus (EOLS), Arbutus Biopharma (ABUS), Trevena (TRVN), IDEAYA Biosciences (IDYA), Zynerba Pharmaceuticals (ZYNE), BIOFRONTERA AG/ADR (BFRA), Cerecor (CERC), Rockwell Medical (RMTI), Harrow Health (HROW) and Sierra Oncology (SRRA). View all competitors. What other stocks do shareholders of Advaxis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Anavex Life Sciences (AVXL), Celgene (CELG), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), Novavax (NVAX) and Opko Health (OPK). Who are Advaxis' key executives? Advaxis' management team includes the following people: Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)Mr. Anthony A. Lombardo, Exec. Officer (Age 70)Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58) What is Advaxis' stock symbol? Advaxis trades on the NASDAQ under the ticker symbol "ADXS." Who are Advaxis' major shareholders? Advaxis' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.41%) and Private Advisor Group LLC (0.33%). Company insiders that own Advaxis stock include Robert Petit and Roni Appel. View institutional ownership trends for Advaxis. Which major investors are buying Advaxis stock? ADXS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., and Private Advisor Group LLC. View insider buying and selling activity for Advaxis. How do I buy shares of Advaxis? Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Advaxis' stock price today? One share of ADXS stock can currently be purchased for approximately $0.71. How big of a company is Advaxis? Advaxis has a market capitalization of $42.78 million and generates $20.88 million in revenue each year. Advaxis employs 58 workers across the globe. What is Advaxis' official website? The official website for Advaxis is www.advaxis.com. How can I contact Advaxis? Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
